The US launch of Pfizer's Inflectra has been an early case study for the US biosimilar market, and some biosimilar manufacturers and payers say market access challenges are worrying.
International reference pricing has become something of a fixture as payers around the world grapple with rising healthcare costs. The landscape is becoming more complex as the practice spreads further into emerging markets, reference baskets get bigger, and calls for pricing transparency grow louder. Scrip examines some of the problems companies face and some of the ways they can adapt, including through new technology, revised approaches to launching new products and better relations with stakeholders.
You could be forgiven for thinking that Brexit was the only story in town on the European regulatory front in 2017, but there were of course plenty of other important developments during the year.
As China enacts reforms to open up to novel drugs, companies must rapidly change their approaches and adopt new business models to seize the window of opportunity, industry insiders tell a recent partnering event in the country.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.